ADMA Biologics, Inc.
ADMA
$17.10
-$0.20-1.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.72% | 51.10% | 734.15% | 1,299.42% | 603.25% |
| Total Depreciation and Amortization | 0.54% | -6.86% | -7.82% | -7.27% | -2.43% |
| Total Amortization of Deferred Charges | -29.52% | -24.90% | -68.62% | -65.05% | -66.96% |
| Total Other Non-Cash Items | 172.43% | 276.55% | -369.04% | 14.79% | 9.31% |
| Change in Net Operating Assets | -371.24% | -131.46% | 280.77% | -520.20% | 267.58% |
| Cash from Operations | -53.69% | -787.06% | 185.37% | 108.83% | 853.36% |
| Capital Expenditure | -17.23% | -100.30% | -130.33% | -39.50% | -136.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 64.88% | -26.67% | 103.33% | -- | -- |
| Cash from Investing | -6.85% | -99.83% | -95.45% | -45.05% | -171.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 81.08% | -- | -- |
| Issuance of Common Stock | 523.56% | -90.18% | 5,437.50% | 812.02% | -29.87% |
| Repurchase of Common Stock | -71.86% | -191.92% | -88.86% | -456.73% | -206.64% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 94.53% | -- | -- |
| Cash from Financing | 113.26% | -392.54% | 20.44% | -6,221.88% | -250.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -56.52% | -423.01% | 172.09% | -113.20% | 741.44% |